A mielofibrózisban szenvedõ betegek kezelésének lehetõségei és korlátai

Gábor Körösmezey, Gabriella Gyõri, Gábor Rudas, Hanna Eid, Zsolt Nagy, J. Demeter

Research output: Article

1 Citation (Scopus)

Abstract

Primary myelofibrosis has the worst outcome among classical chronic myeloproliferative neoplasms. The past decade has brought numerous discoveries elucidating the role of proliferative mutations in disease pathogenesis. Mutations of the genes JAK2, MPL and CALR are present in about 90 percent of all primary myelofibrosis cases. The prognosis of myelofibrosis is considered heterogeneous, the expected survival of patients may range from one year to more than a decade based on several prognostic factors. Estimated survival can be assessed based on clinical prognostic scores. The aim of treatment is to reduce mortality and to alleviate the main aspects of disease-associated morbidity, e.g. anemia, splenomegalia and systemic symptoms. The effect of conventionally used cytoreductive agent hydroxyurea is usually transient. Use of allogeneic hematopoietic stem cell transplantation is limited by significant procedure-associated mortality. JAK2 tyrosine kinase inhibitors are the first treatment modality with evidence of improved overall survival, however, even these molecularly targeted therapies have failed to bring complete and permanent remission for the majority of myelofibrosis patients. Further improvement in overall survival for myelofibrosis can be expected from better understanding of the underlying molecular pathology and novel molecular therapeutic targets.

Original languageHungarian
Pages (from-to)47-55
Number of pages9
JournalMagyar onkologia
Volume61
Issue number1
Publication statusPublished - márc. 8 2017

Fingerprint

Primary Myelofibrosis
Survival
Therapeutics
Mutation
Hydroxyurea
Molecular Pathology
Mortality
Hematopoietic Stem Cell Transplantation
Protein-Tyrosine Kinases
Anemia
Morbidity
Genes
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Körösmezey, G., Gyõri, G., Rudas, G., Eid, H., Nagy, Z., & Demeter, J. (2017). A mielofibrózisban szenvedõ betegek kezelésének lehetõségei és korlátai. Magyar onkologia, 61(1), 47-55.

A mielofibrózisban szenvedõ betegek kezelésének lehetõségei és korlátai. / Körösmezey, Gábor; Gyõri, Gabriella; Rudas, Gábor; Eid, Hanna; Nagy, Zsolt; Demeter, J.

In: Magyar onkologia, Vol. 61, No. 1, 08.03.2017, p. 47-55.

Research output: Article

Körösmezey, G, Gyõri, G, Rudas, G, Eid, H, Nagy, Z & Demeter, J 2017, 'A mielofibrózisban szenvedõ betegek kezelésének lehetõségei és korlátai', Magyar onkologia, vol. 61, no. 1, pp. 47-55.
Körösmezey G, Gyõri G, Rudas G, Eid H, Nagy Z, Demeter J. A mielofibrózisban szenvedõ betegek kezelésének lehetõségei és korlátai. Magyar onkologia. 2017 márc. 8;61(1):47-55.
Körösmezey, Gábor ; Gyõri, Gabriella ; Rudas, Gábor ; Eid, Hanna ; Nagy, Zsolt ; Demeter, J. / A mielofibrózisban szenvedõ betegek kezelésének lehetõségei és korlátai. In: Magyar onkologia. 2017 ; Vol. 61, No. 1. pp. 47-55.
@article{a0009cc0298047639592371c27c7450b,
title = "A mielofibr{\'o}zisban szenved{\~o} betegek kezel{\'e}s{\'e}nek lehet{\~o}s{\'e}gei {\'e}s korl{\'a}tai",
abstract = "Primary myelofibrosis has the worst outcome among classical chronic myeloproliferative neoplasms. The past decade has brought numerous discoveries elucidating the role of proliferative mutations in disease pathogenesis. Mutations of the genes JAK2, MPL and CALR are present in about 90 percent of all primary myelofibrosis cases. The prognosis of myelofibrosis is considered heterogeneous, the expected survival of patients may range from one year to more than a decade based on several prognostic factors. Estimated survival can be assessed based on clinical prognostic scores. The aim of treatment is to reduce mortality and to alleviate the main aspects of disease-associated morbidity, e.g. anemia, splenomegalia and systemic symptoms. The effect of conventionally used cytoreductive agent hydroxyurea is usually transient. Use of allogeneic hematopoietic stem cell transplantation is limited by significant procedure-associated mortality. JAK2 tyrosine kinase inhibitors are the first treatment modality with evidence of improved overall survival, however, even these molecularly targeted therapies have failed to bring complete and permanent remission for the majority of myelofibrosis patients. Further improvement in overall survival for myelofibrosis can be expected from better understanding of the underlying molecular pathology and novel molecular therapeutic targets.",
author = "G{\'a}bor K{\"o}r{\"o}smezey and Gabriella Gy{\~o}ri and G{\'a}bor Rudas and Hanna Eid and Zsolt Nagy and J. Demeter",
year = "2017",
month = "3",
day = "8",
language = "Hungarian",
volume = "61",
pages = "47--55",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - A mielofibrózisban szenvedõ betegek kezelésének lehetõségei és korlátai

AU - Körösmezey, Gábor

AU - Gyõri, Gabriella

AU - Rudas, Gábor

AU - Eid, Hanna

AU - Nagy, Zsolt

AU - Demeter, J.

PY - 2017/3/8

Y1 - 2017/3/8

N2 - Primary myelofibrosis has the worst outcome among classical chronic myeloproliferative neoplasms. The past decade has brought numerous discoveries elucidating the role of proliferative mutations in disease pathogenesis. Mutations of the genes JAK2, MPL and CALR are present in about 90 percent of all primary myelofibrosis cases. The prognosis of myelofibrosis is considered heterogeneous, the expected survival of patients may range from one year to more than a decade based on several prognostic factors. Estimated survival can be assessed based on clinical prognostic scores. The aim of treatment is to reduce mortality and to alleviate the main aspects of disease-associated morbidity, e.g. anemia, splenomegalia and systemic symptoms. The effect of conventionally used cytoreductive agent hydroxyurea is usually transient. Use of allogeneic hematopoietic stem cell transplantation is limited by significant procedure-associated mortality. JAK2 tyrosine kinase inhibitors are the first treatment modality with evidence of improved overall survival, however, even these molecularly targeted therapies have failed to bring complete and permanent remission for the majority of myelofibrosis patients. Further improvement in overall survival for myelofibrosis can be expected from better understanding of the underlying molecular pathology and novel molecular therapeutic targets.

AB - Primary myelofibrosis has the worst outcome among classical chronic myeloproliferative neoplasms. The past decade has brought numerous discoveries elucidating the role of proliferative mutations in disease pathogenesis. Mutations of the genes JAK2, MPL and CALR are present in about 90 percent of all primary myelofibrosis cases. The prognosis of myelofibrosis is considered heterogeneous, the expected survival of patients may range from one year to more than a decade based on several prognostic factors. Estimated survival can be assessed based on clinical prognostic scores. The aim of treatment is to reduce mortality and to alleviate the main aspects of disease-associated morbidity, e.g. anemia, splenomegalia and systemic symptoms. The effect of conventionally used cytoreductive agent hydroxyurea is usually transient. Use of allogeneic hematopoietic stem cell transplantation is limited by significant procedure-associated mortality. JAK2 tyrosine kinase inhibitors are the first treatment modality with evidence of improved overall survival, however, even these molecularly targeted therapies have failed to bring complete and permanent remission for the majority of myelofibrosis patients. Further improvement in overall survival for myelofibrosis can be expected from better understanding of the underlying molecular pathology and novel molecular therapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=85045189268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045189268&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 47

EP - 55

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -